Supernus Pharmaceuticals Gross Profit 2011-2024 | SUPN

Supernus Pharmaceuticals gross profit from 2011 to 2024. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services.
Supernus Pharmaceuticals Annual Gross Profit
(Millions of US $)
2023 $524
2022 $580
2021 $505
2020 $468
2019 $376
2018 $394
2017 $287
2016 $203
2015 $139
2014 $87
2013 $11
2012 $1
2011 $1
2010 $0
Supernus Pharmaceuticals Quarterly Gross Profit
(Millions of US $)
2024-09-30 $158
2024-06-30 $150
2024-03-31 $127
2023-12-31 $145
2023-09-30 $134
2023-06-30 $114
2023-03-31 $130
2022-12-31 $144
2022-09-30 $151
2022-06-30 $150
2022-03-31 $135
2021-12-31 $142
2021-09-30 $130
2021-06-30 $116
2021-03-31 $116
2020-12-31 $125
2020-09-30 $134
2020-06-30 $118
2020-03-31 $91
2019-12-31 $96
2019-09-30 $97
2019-06-30 $101
2019-03-31 $82
2018-12-31 $112
2018-09-30 $99
2018-06-30 $96
2018-03-31 $87
2017-12-31 $84
2017-09-30 $76
2017-06-30 $72
2017-03-31 $55
2016-12-31 $59
2016-09-30 $53
2016-06-30 $49
2016-03-31 $42
2015-12-31 $41
2015-09-30 $37
2015-06-30 $34
2015-03-31 $27
2014-12-31 $29
2014-09-30 $21
2014-06-30 $28
2014-03-31 $9
2013-12-31 $9
2013-09-30 $1
2013-06-30 $0
2013-03-31 $0
2012-12-31 $1
2012-09-30 $0
2012-06-30 $0
2012-03-31 $0
2011-12-31 $0
2011-09-30 $0
2011-06-30 $1
2011-03-31
2010-12-31
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $1.962B $0.608B
Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.044B 6.25
Dr Reddy's Laboratories (RDY) India $11.978B 22.92
BridgeBio Pharma (BBIO) United States $4.260B 0.00
Bausch Health Cos (BHC) Canada $3.012B 2.18
Amphastar Pharmaceuticals (AMPH) United States $2.097B 12.61
Taysha Gene Therapies (TSHA) United States $0.434B 30.29
Personalis (PSNL) United States $0.261B 0.00
Assembly Biosciences (ASMB) United States $0.098B 0.00
Sol-Gel Technologies (SLGL) Israel $0.012B 0.00
Evoke Pharma (EVOK) United States $0.007B 0.00
Teligent (TLGT) United States $0.000B 0.00